Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · Real-Time Price · USD

17.03

0.00 (0.00%)

Aug 26, 2026, 4:00 PM EDT - Market closed

Theravance Biopharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	104.31	107.46	64.38	57.42	51.35	55.31
Revenue Growth	35.11%	66.92%	12.12%	11.84%	-7.17%	-23.03%
Gross Profit	78.3	70.05	26.74	16.8	-12.05	-138.35
Operating Income	9.55	-3.6	-42.44	-53.65	-79.12	-237.64
Net Income	53.81	105.9	-56.42	-55.19	872.13	-199.43
Earnings Per Share	1.05	2.06	-1.15	-1.00	11.85	-2.87
EPS Growth	300.80%	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
United States	74.96	64.38	57.2	51.12	55.27
Europe	32.5	-	0.22	0.22	0.04
Total	107.46	64.38	57.42	51.35	55.31

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	387.66	326.49	88.35	102.43	327.48	173.47
Total Debt	38.57	42.7	49.82	49.16	52.16	669.52
Net Cash (Debt)	349.09	283.78	38.53	53.27	275.32	-496.05
Net Cash Growth	19.41%	636.52%	-27.67%	-80.65%	-	-
Net Cash Per Share	6.73	5.51	0.79	0.96	3.74	-7.14

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	53.74	238.54	-11.54	-27	-186.99	-207.86
Capital Expenditures	-0.01	-0.04	-0.33	-2.49	-0.57	-3.41
Free Cash Flow	53.73	238.5	-11.87	-29.49	-187.56	-211.26
Free Cash Flow Growth	-78.05%	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	75.06%	65.19%	41.53%	29.26%	-23.46%	-250.12%
Operating Margin	9.16%	-3.35%	-65.91%	-93.43%	-154.09%	-429.65%
Pretax Margin	56.48%	120.27%	-69.30%	-85.80%	-180.76%	-479.51%
Profit Margin	51.58%	98.54%	-87.63%	-96.11%	1698.54%	-360.55%
FCF Margin	51.51%	221.93%	-18.43%	-51.35%	-365.29%	-381.96%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 27, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	16.30	8.95	-	-	0.87	-
Forward PE	4.29	25.83	29.96	29.96	29.96	-
P/FCF Ratio	16.45	3.98	-	-	-	-
PS Ratio	8.48	8.82	7.19	9.75	14.70	14.72